Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Market Update

Julia Lee
January 11, 2017

Market Update

Julia Lee
January 9, 2017

Market Update

Julia Lee
January 6, 2017

Market Update

Julia Lee
January 5, 2017

Market Update

Julia Lee
December 23, 2016

Market Update

Julia Lee
December 22, 2016

Stock Rankings 2017 – Bell Potter

Bell Direct
December 22, 2016

Market Open

Julia Lee
December 21, 2016

Market Update

Julia Lee
December 19, 2016

Market Update

Julia Lee
December 16, 2016

Market Update

Julia Lee
December 15, 2016

Market update 14 December

Julia Lee
December 14, 2016